OH-Glu-Val-Cit-PAB-MMAE

• CAT Number: I042639
• CAS Number: 1895916-23-0
• Molecular Formula: C63H100N10O15
• Molecular Weight: 1237.53
• Purity: ≥95%
• Synonyms: 5-[[(2S)-1-[[(2S)-5-(carbamoylamino)-1-[4-[[[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-methylcarbamoyl]oxymethyl]anilino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoic acid
• InChI: InChI=1S/C63H100N10O15/c1-15-39(8)54(47(86-13)34-49(75)73-33-21-25-46(73)56(87-14)40(9)57(79)66-41(10)55(78)43-22-17-16-18-23-43)71(11)61(83)52(37(4)5)70-60(82)53(38(6)7)72(12)63(85)88-35-42-28-30-44(31-29-42)67-58(80)45(24-20-32-65-62(64)84)68-59(81)51(36(2)3)69-48(74)26-19-27-50(76)77/h16-18,22-23,28-31,36-41,45-47,51-56,78H,15,19-21,24-27,32-35H2,1-14H3,(H,66,79)(H,67,80)(H,68,81)(H,69,74)(H,70,82)(H,76,77)(H3,64,65,84)/t39-,40+,41+,45-,46-,47+,51-,52-,53-,54-,55+,56+/m0/s1
• InChIKey: XKQGZQVGYMIHEK-GJIHENSZSA-N
• SMILES: CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@@H]([C@@H](C)C(=O)N[C@H](C)[C@H](C2=CC=CC=C2)O)OC)OC)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N(C)C(=O)OCC3=CC=C(C=C3)NC(=O)[C@H](CCCNC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)CCCC(=O)O

OH-Glu-Val-Cit-PAB-MMAE（Cat No.:I042639）is a compound utilized in the synthesis of antibody-drug conjugates (ADCs). It comprises a cleavable linker sequence—Glu-Val-Cit-PAB—and monomethyl auristatin E (MMAE), a potent microtubule inhibitor. The Glu-Val-Cit-PAB linker is designed to be stable in the bloodstream but cleaved by specific intracellular proteases upon internalization into target cells, thereby releasing the cytotoxic MMAE to induce cell death. This design allows for targeted delivery of the cytotoxic agent, minimizing systemic toxicity. Such ADCs have shown efficacy in treating various cancers by selectively targeting and killing tumor cells while sparing healthy tissues.